Given the regulatory role of IGF2 in fibroblast-mediated immunosuppression and our animal experiments showing the ability of linsitinib to enhance the efficacy of ICB, it is proposed that the combination of IGF1R inhibitors and ICB in clinical settings may yield more favorable therapeutic benefits for patients with cancer, especially those with high levels of IGF2 in tumor tissues or blood. This evidence concerns the gene IGF2 and cancer.